Pre Series-A
Heart failure is a global epidemic, affecting more than 64 million people worldwide. Recent advances managed to decrease mortality, but hospitalizations are on the rise. Furthermore, the capacity for follow-up examinations is reduced due to limited resources in the healthcare sector. This not only leads to bad quality of life for patients, but also to increased health care costs for hospitals and health care providers.
ProCarement provides the app ProHerz, the first and only cardiological digital health application (DiGA) in Germany. ProHerz connects with monitoring hardware to collect patient data and classifies current state of health in a traffic light system. The costs of this app is reimbursed by health insurances.
For patients ProHerz is easy to use. Their doctors can see in real time how the heart problems of their patients are developing and can thus initiate adjustments in therapy i.e. medication, recommendations concerning nutrition, possible follow-up examinations etc. at any time.
ProCarement’s ProHerz is the first and only cardiological DiGA in Germany, which can thus be prescribed as an “app on prescription”. ProCarement is in the listing by the BfArM DiGA directory (bfarm.de) since mid-May 2023.
Cardiologists prescribe the app to their patients. A monthly fee (recurring) is charged for this, which is reimbursed by health insurance companies. The fee is currently 605€ per quarter for the first prescription, 495 € per quarter for follow-up prescriptions.
Currently, there are four million patients with heart failures/insufficiencies in Germany. Other countries in the EU (e.g. France, Austria) plan to adopt a similar legal regime as the German DiGA act.
Potential candidates are Pharma and MedTech companies
Founder & CEO
COO
CFO
This document is non-binding preliminary information that provides an initial impression of the financing options offered. Neither this document nor the statements made by us in this context can be a sufficient basis for a financing decision. Investors should examine the possible investments themselves. Responsibility based on own analysis. This document does not constitute a sales prospectus, a public offer of an investment, an invitation to submit an offer, investment advice or investment brokerage. In providing this information, we make no representations, warranties or other contractual or quasi-contractual obligations, including with respect to the completeness, content or accuracy of the information reproduced in this document. This document is to be treated confidentially and may not be reproduced in whole or in part, passed on to third parties or published.
Dr. Andreas R. Boué
Bleiben Sie über die neusten Trends und Updates der Industrie mit unserem monatlichen Newsletter informiert.
© 2024 G8Way GmbH, Wien & München
